Skip to main content


Welcome to contact Moberg Pharma for collaboration/licensing in the following projects:

  • MOB-015 - Onychomycosis (nail fungus) – Phase 3 studies are ongoing
    MOB-015 is a new topical treatment for onychomycosis (nail fungus) with antifungal, keratolytic, and emollient properties. The company’s patented formulation technology facilitates delivery of high concentrations of a proven antifungal substance (terbinafine) into and through the nail. Since MOB-015 is applied locally, adverse events associated with oral treatments can be avoided. A recent survey of physicians in the USA indicated that there is a strong demand for better topical treatment and that a majority of physicians would prefer MOB-015 over existing treatment options, whether topical medications or tablets, if the Phase 3 results meet the target profile. The company estimates the sales potential of MOB-015 to USD 250–500 million annually.

    Several attractive licensing agreements for MOB-015 are already in place in Europe (Bayer), Japan (Taisho), South Korea (Dongkoo) and Canada (Cipher) and we look forward to entering into more exciting partnerships in the future.

  • BUPI - Oral mucositis (pain management) – Phase 3 preparations are ongoing
    BUPI is a innovative, patented formulation with the proven substance bupivacaine, in the form of a lozenge, for the treatment of pain in the oral cavity. In January 2016, Moberg Pharma reported positive results from a Phase 2 study in which BUPI was evaluated for cancer patients with oral mucositis as the first indication. Moberg Pharma estimates that the product has sales potential of USD 100–200 million annually, assuming successful commercialization in oral mucositis and at least one further indication.